Differences

This shows you the differences between two versions of the page.

--- home:food:aim_health:aging [02.09.2019] – [with additional studies] sallieq
+++ home:food:aim_health:aging [02.11.2019] – [with additional studies] sallieq
@@ Line 7: / Line 7: @@
 ===== with additional studies =====
- In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>long:24535009}}))
  Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}}))
@@ Line 18: / Line 16: @@
 The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}}))
-Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>long:26239632}}))
+Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>long:26239632}}))
+ In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>long:24535009}}))
 ==== General research on aging ====

home/food/aim_health/aging.txt · Last modified: 09.14.2022 by 127.0.0.1